Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tomassetti, Sarah
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)	Active, not recruiting	3	194	Europe, Canada, Japan, US, RoW	Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo	Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.	Immune Thrombocytopenia	06/25	11/26
APPELHUS, NCT04889430 / 2020-005186-13: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy	Recruiting	3	50	Europe, Japan, US, RoW	Iptacopan, LNP023	Novartis Pharmaceuticals, Novartis Pharma AG	Atypical Hemolytic Uremic Syndrome	09/28	03/29
NCT05002777 / 2021-001671-16: Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) Jul 2024 - Dec 2024 : Data from trial for warm autoimmune hemolytic anemia	Active, not recruiting	2	22	Europe, US, RoW	rilzabrutinib, PRN1008/SAR444671	Sanofi, Sanofi Aventis Recherche et Developpement	Warm Autoimmune Hemolytic Anemia (wAIHA)	05/24	05/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Active, not recruiting	2	196	US	asciminib, ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	09/25	10/27